ArticleCommunications medicine2026
A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glucagon-like Peptide-1 Receptor Agonists and Dual Incretin Therapies Across HFpEF and Cardiovascular Outcomes Trials in Patients with Obesity.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart damage caused by cancer treatment can lead to heart failure, hospital admission, and death. Medications known as glucagon-like peptide-1 receptor agonists are widely used to treat type 2 diabetes with cardioprotective potentials. Whether these medications can reduce heart damage related to cancer therapy remains uncertain. This study aims to evaluate the association between glucagon-like peptide-1 receptor agonist use and the risk of heart damage in patients receiving cancer treatments.
methodsWe conducted a retrospective cohort study using a large international real-world health records database from January 2017 to March 2025. Adult patients with cancer who received heart-damaging cancer therapies were included and grouped according to use of glucagon-like peptide-1 receptor agonists. Patients were carefully matched to ensure comparable baseline characteristics. Clinical outcomes over 12 months were analyzed using time-to-event statistical models, with additional subgroup and sensitivity analyses.
resultsHere we show that use of glucagon-like peptide-1 receptor agonists is associated with a significantly lower risk of cancer therapy-related heart damage, death from any cause, hospital admission, blocked blood vessels, blood clots, and overall cardiovascular complications. The protective effects are most pronounced in women, younger patients, individuals with excess body weight, and those with type 2 diabetes. Benefits are observed across different cancer treatments and are particularly evident with anthracycline chemotherapy.
conclusionsGlucagon-like peptide-1 receptor agonist use is associated with reduced heart damage during cancer treatment, suggesting a potential role for these medications in protecting cardiovascular health among cancer patients, especially those with type 2 diabetes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.